Program
silodosin
Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.
Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.
Drug pageSilodosin: every studyMany companies study it; this page follows only the 17 they lead. All 40 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 60 open or running | phase 3since Sep 14, 2005 | Sep 14, 2005 | none ahead |
| JW Pharmaceuticalits history only | 50 open or running | phase 4since Oct 25, 2010 | Oct 25, 2010 | none ahead |
| Kissei Pharmaceuticalits history only | 20 open or running | phase 2since Oct 15, 2010 | Oct 15, 2010 | none ahead |
| RECORDATI GROUPits history only | 20 open or running | phase 4since Dec 21, 2012 | Aug 2, 2006 | none ahead |
| Shanghai Huilun Pharmaceuticalits history only | 10 open or running | phase 4since Aug 14, 2025 | Aug 14, 2025 | none ahead |
| Xintian Pharmaceuticalits history only | 10 open or running | phase 4since Sep 19, 2022 | Sep 19, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2005First studies: 3 phase 3 studies in Prostatic HyperplasiaNew to AbbVieAbbVie · NCT00224133, NCT00224120, NCT00224107
- Aug 2, 2006RECORDATI GROUP’s first study: phase 3 study in Prostatic HyperplasiaNew to RECORDATI GROUPRECORDATI GROUP · NCT00359905 · 1,228 enrolled · United Kingdom
- Aug 21, 2008Phase 2 study in ProstatitisAbbVie · NCT00740779 · 153 enrolled · United States
- Nov 17, 2008Phase 2 study in NocturiaAbbVie · NCT00793819 · 215 enrolled · United States
- Jun 14, 2010Phase 2 study in Ureteral CalculiAbbVie · NCT01144949 · 239 enrolled · United States
- Oct 15, 2010Kissei Pharmaceutical’s first study: phase 2 study in Prostatic HyperplasiaNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01222650 · 400 enrolled · Japan
- Oct 25, 2010JW Pharmaceutical’s first studies: 2 phase 4 studiesNew to JW PharmaceuticalJW Pharmaceutical · NCT01228370, NCT01260129
- Dec 7, 2010Phase 4 study in Prostatic HyperplasiaJW Pharmaceutical · NCT01259531 · 100 enrolled · Korea, Republic of
- Feb 6, 2012Phase 4 study in UreterolithiasisJW Pharmaceutical · NCT01533389 · 114 enrolled · Korea, Republic of
- Feb 21, 2012Phase 2 study in Urinary CalculiKissei Pharmaceutical · NCT01539265 · 300 enrolled · Japan
- Dec 21, 2012Phase 4 study in Prostatic HyperplasiaRECORDATI GROUP · NCT01757769 · 1,036 enrolled · Italy
- Mar 31, 2014Phase 4 study in NocturiaJW Pharmaceutical · NCT02106182 · 135 enrolled · Korea, Republic of
- Sep 19, 2022Xintian Pharmaceutical’s first study: phase 4 study in Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsNew to Xintian PharmaceuticalXintian Pharmaceutical · NCT05551221 · 110 enrolled · China
- Aug 14, 2025Shanghai Huilun Pharmaceutical’s first study: phase 4 study in Prostatic HyperplasiaNew to Shanghai Huilun PharmaceuticalShanghai Huilun Pharmaceutical · NCT07134907 · 110 enrolled · China
TargetBeta
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on ADRA1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07134907Prostatic Hyperplasia · China | 4 | Completed | Shanghai Huilun Pharmaceutical | Jul 9, 2024 | 110 |
| NCT05551221Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms · China | 4 | Completed | Xintian Pharmaceutical | Sep 10, 2024 | 110 |
| NCT02106182Nocturia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Mar 2, 2016 | 135 |
| NCT01757769Prostatic Hyperplasia · Italy | 4 | Completed | RECORDATI GROUP | Mar 2013 | 1,036 |
| NCT01539265Urinary Calculi · Japan | 2 | Completed | Kissei Pharmaceutical | 300 | |
| NCT01533389Ureterolithiasis · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Mar 2012 | 114 |
| NCT01259531Prostatic Hyperplasia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Sep 2011 | 100 |
| NCT01260129Prostatic Hyperplasia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Nov 2010 | 424 |
| NCT01228370Urinary Bladder, Neurogenic · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Jan 2012 | 95 |
| NCT01222650Prostatic Hyperplasia · Japan | 2 | Completed | Kissei Pharmaceutical | 400 | |
| NCT01144949Ureteral Calculi · United States | 2 | Completed | AbbVie | Jul 2012 | 239 |
| NCT00793819Nocturia · United States | 2 | Completed | AbbVie | Oct 2009 | 215 |
| NCT00740779Prostatitis · United States | 2 | Completed | AbbVie | Oct 2009 | 153 |
| NCT00359905Prostatic Hyperplasia · United Kingdom | 3 | Completed | RECORDATI GROUP | May 2007 | 1,228 |
| NCT00224133Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | Apr 2007 | 661 |
| NCT00224120Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | May 2006 | 462 |
| NCT00224107Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | Aug 2006 | 461 |
How it is read
Names in the registry
- “Silodosin”, 12 entries
- “silodosin”, 5 entries
- “KSO-0400”, 2 entries
- “Silodosin Capsules”, 1 entry
- “Silodosin 8 mg”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 9 studies
- Nocturia, 2 studies
- Lower Urinary Tract Symptoms, 1 study
- Ureteral Calculi, 1 study
- Ureterolithiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.